Evidence map›Paper›PMID 36769709›Full record

ArticleJournal of clinical medicine2023

Comparison of Contributors to Mortality Differences in SLE Patients with Different Initial Disease Activity: A Larger Multicenter Cohort Study.

Ziyi Jin, Zheng Chen, Wenyou Pan, Lin Liu, Min Wu, Huaixia Hu, Xiang Ding, Hua Wei, Yaohong Zou, Xian Qian and 9 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ziyi JinDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.ORCID 0000-0002-8091-2266
Zheng ChenDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.
Wenyou PanDepartment of Rheumatology, Huai'an First People's Hospital, Huai'an 223001, China.
Lin LiuDepartment of Rheumatology, Xuzhou Central Hospital, Xuzhou 221008, China.
Min WuDepartment of Rheumatology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Huaixia HuDepartment of Rheumatology, Lianyungang Second People's Hospital, Lianyungang 222000, China.
Xiang DingDepartment of Rheumatology, Lianyungang First People's Hospital, Lianyungang 222002, China.
Hua WeiDepartment of Rheumatology, Northern Jiangsu People's Hospital, Yangzhou 225007, China.
Yaohong ZouDepartment of Rheumatology, Wuxi People's Hospital, Wuxi 214028, China.
Xian QianDepartment of Rheumatology, Jiangsu Province Hospital of TCM, Nanjing 210004, China.
Meimei WangDepartment of Rheumatology, Southeast University Zhongda Hospital, Nanjing 210009, China.
Jian WuDepartment of Rheumatology, The First Affiliated Hospital of Soochow University, Suzhou 215005, China.
Juan TaoDepartment of Rheumatology, Wuxi TCM Hospital, Wuxi 214177, China.
Jun TanDepartment of Rheumatology, Zhenjiang First People's Hospital, Zhenjiang 212050, China.
Zhanyun DaDepartment of Rheumatology, Affiliated Hospital of Nantong University, Nantong 226001, China.
Miaojia ZhangDepartment of Rheumatology, Jiangsu Province Hospital, Nanjing 210029, China.
Jing LiDepartment of Rheumatology, Affiliated Hospital of Jiangsu University, Zhenjiang 212050, China.
Xuebing FengDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.
Lingyun SunDepartment of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.

Funding

National Key R&D Program of China 2020YFA0710800the Key Program of National Natural Science Foundation of China 81930043the Major International (Regional) Joint Research Project of China 81720108020
6 · The paper itself

Abstract

To explore the etiology of risk factors and quantify the mortality differences in systemic lupus erythematosus (SLE) patients with different initial disease activity. The Jiangsu Lupus database was established by collecting medical records from first-hospitalized SLE patients during 1999-2009 from 26 centers in Jiangsu province, China, and their survival status every five years. The initial SLEDAI scores [high (>12) vs. low-moderate (≤12)] differences in mortality attributable to risk factors were quantified using population attributable fraction (PAF), relative attributable risk (RAR) and adjusted relative risk (ARR). Among 2446 SLE patients, 83 and 176 deaths were observed in the low-moderate and high activity groups, with mortality rates of 7.7 and 14.0 per 1000 person years, respectively. Anemia was the leading contributor to mortality, with PAFs of 40.4 and 37.5 in the low-moderate and high activity groups, respectively, and explained 23.2% of the mortality differences with an ARR of 1.66 between the two groups. Cardiopulmonary involvement caused the highest PAFs in the low-moderate (20.5%) and high activity (13.6%) groups, explaining 18.3% of the mortality differences. The combination of anemia and cardiopulmonary involvement had the highest RAR, causing 39.8% of the mortality differences (ARR = 1.52) between the two groups. In addition, hypoalbuminemia and a decrease in the creatinine clearance rate accounted for 20-30% of deaths and explained 10-20% of the mortality differences between the two groups, while antimalarial drug nonuse accounted for about 35% of deaths and explained 3.6% of the mortality differences. Anemia, cardiopulmonary involvement and hypoalbuminemia may cause substantial mortality differences across disease activity states, suggesting additional strategies beyond disease activity assessment to monitor SLE outcomes.

Indexed as

attributable riskdisease activitymortalityrelative riskSLE

Identifiers

PMID36769709
PMCPMC9918091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.